Huiyu Pharmaceutical: Three products have obtained market authorization in Germany, Spain, and other countries.

Huayu Pharmaceuticals announced that its subsidiaries, Seacross Pharma Ltd. and Seacross Pharmaceuticals Ltd., have recently obtained approvals from relevant authorities in Germany, Spain, Belgium, and Pakistan for the injection of Diclofenac, Paclitaxel, and Octreotide Acetate. This will help enrich the company's international market product pipeline and expand its international business. However, uncertainties remain about whether significant revenue can be generated in the future due to factors such as product competition and promotional effects. In the short term, this will not have a significant impact on the company's performance.